Bbr Partners Has Decreased Johnson & Johnson (JNJ) Holding By $454,212; Amedica (AMDA) Shorts Raised By 0.9%

December 6, 2017 - By wolcottdaily

Bbr Partners Llc decreased Johnson & Johnson (JNJ) stake by 45.92% reported in 2017Q2 SEC filing. Bbr Partners Llc sold 3,441 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The Bbr Partners Llc holds 4,052 shares with $536,000 value, down from 7,493 last quarter. Johnson & Johnson now has $378.53B valuation. The stock increased 0.88% or $1.23 during the last trading session, reaching $140.9. About 3.16M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since December 6, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Amedica Corporation (NASDAQ:AMDA) had an increase of 0.9% in short interest. AMDA’s SI was 1.77 million shares in December as released by FINRA. Its up 0.9% from 1.75 million shares previously. With 2.10M avg volume, 1 days are for Amedica Corporation (NASDAQ:AMDA)’s short sellers to cover AMDA’s short positions. The SI to Amedica Corporation’s float is 7.2%. The stock decreased 0.47% or $0.02 during the last trading session, reaching $3.17. About 44,012 shares traded. Amedica Corporation (NASDAQ:AMDA) has declined 73.26% since December 6, 2016 and is downtrending. It has underperformed by 89.96% the S&P500.

Among 2 analysts covering Amedica (NASDAQ:AMDA), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Amedica had 5 analyst reports since August 14, 2015 according to SRatingsIntel. On Monday, November 27 the stock rating was downgraded by Ladenburg Thalmann to “Neutral”. Maxim Group downgraded the stock to “Hold” rating in Monday, September 25 report. The rating was maintained by Needham with “Buy” on Friday, August 14. As per Tuesday, January 5, the company rating was initiated by Ladenburg Thalmann. The firm earned “Buy” rating on Thursday, November 10 by Maxim Group.

Amedica Corporation, a commercial-stage biomaterial company, develops, makes, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the United States, Europe, and South America. The company has market cap of $9.60 million. The firm offers Valeo silicon nitride spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; and a line of non-silicon nitride spinal surgery products for the treatment of deformity and degenerative spinal procedures. It currently has negative earnings. It also develops femoral heads for use in total hip replacements; and femoral condyle components for use in total knee replacements.

Investors sentiment decreased to 0.83 in Q2 2017. Its down 0.03, from 0.86 in 2017Q1. It dived, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. 1.73 billion shares or 0.03% less from 1.73 billion shares in 2017Q1 were reported. Utd Fire Group Inc Inc owns 38,000 shares. Summit Asset Mngmt Ltd Liability invested in 0.83% or 11,889 shares. Paragon Capital Management Ltd Liability Co invested in 102,122 shares or 4.33% of the stock. California State Teachers Retirement Systems owns 5.13 million shares. 318,909 were accumulated by Brown Brothers Harriman And. Fjarde Ap accumulated 627,126 shares or 1.67% of the stock. Hallmark Inc holds 147,435 shares. Alpine Woods Capital Limited Liability Com, New York-based fund reported 134,022 shares. Florida-based Eagle Asset has invested 0.68% in Johnson & Johnson (NYSE:JNJ). Highstreet Asset Mngmt accumulated 117,064 shares or 1.67% of the stock. Lehman Financial Resource holds 0.68% in Johnson & Johnson (NYSE:JNJ) or 9,067 shares. Papp L Roy Associates, a Arizona-based fund reported 85,389 shares. Tctc Limited Liability Corp has 0.77% invested in Johnson & Johnson (NYSE:JNJ). Richard Bernstein Advsr Limited Liability invested in 0.89% or 87,863 shares. Biondo Invest Advsrs Lc accumulated 3,151 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :